BACKGROUND: Statin use and serum cholesterol reduction have been proposed as preventions for dementia and mild cognitive impairment (MCI). METHODS: 1604 and 1345 eligible participants from the Baltimore Longitudinal Study of Aging (BLSA) were followed after age 50 for a median time of around 25 years, to examine the incidence of dementia (n=259) and MCI (n=138), respectively. Statin use (ever-use and time-dependent use), total cholesterol levels (TC; first visit and time-dependent), TC change trajectory from first visit and high-density lipoprotein (HDL-C):TC ratio (first visit and time-dependent) were the main exposures of interest. Cox proportional hazards models were used. RESULTS: Participants with incident dementia had a higher first-visit TC compared with participants who remained free of dementia and MCI, while first-visit TC was higher among statin ever-users compared with never-users (age-unadjusted associations). Statin users had a two- to threefold lower risk of developing dementia (HR=0.41; 95% CI 0.18 to 0.92), but not MCI, when considering time-dependent 'statin use' with propensity score model adjustment. This association remained significant independently of serum cholesterol exposures. An elevated first-visit TC was associated with reduced MCI risk (upper quartile (Q(4)) vs Q(1): HR=0.51; 95% CI 0.29 to 0.90). Compared with the lowest quartile (Q(1): 0.00-0.19), HDL-C:TC (time-dependent) in (Q(2): 0.19-0.24) was associated with reduced MCI risk (HR=0.58; 95% CI 0.34 to 0.98). Among men only, TC decline from first visit was significantly associated with increased dementia risk (HR=4.21; 95% CI 1.28 to 13.85). CONCLUSIONS: Statins may have multifactorial effects on dementia but not MCI risk. Future interventions may be warranted, and research should focus on optimal serum TC, HDL-C:TC ratio and TC change trajectories.
BACKGROUND: Statin use and serum cholesterol reduction have been proposed as preventions for dementia and mild cognitive impairment (MCI). METHODS: 1604 and 1345 eligible participants from the Baltimore Longitudinal Study of Aging (BLSA) were followed after age 50 for a median time of around 25 years, to examine the incidence of dementia (n=259) and MCI (n=138), respectively. Statin use (ever-use and time-dependent use), total cholesterol levels (TC; first visit and time-dependent), TC change trajectory from first visit and high-density lipoprotein (HDL-C):TC ratio (first visit and time-dependent) were the main exposures of interest. Cox proportional hazards models were used. RESULTS:Participants with incident dementia had a higher first-visit TC compared with participants who remained free of dementia and MCI, while first-visit TC was higher among statin ever-users compared with never-users (age-unadjusted associations). Statin users had a two- to threefold lower risk of developing dementia (HR=0.41; 95% CI 0.18 to 0.92), but not MCI, when considering time-dependent 'statin use' with propensity score model adjustment. This association remained significant independently of serum cholesterol exposures. An elevated first-visit TC was associated with reduced MCI risk (upper quartile (Q(4)) vs Q(1): HR=0.51; 95% CI 0.29 to 0.90). Compared with the lowest quartile (Q(1): 0.00-0.19), HDL-C:TC (time-dependent) in (Q(2): 0.19-0.24) was associated with reduced MCI risk (HR=0.58; 95% CI 0.34 to 0.98). Among men only, TC decline from first visit was significantly associated with increased dementia risk (HR=4.21; 95% CI 1.28 to 13.85). CONCLUSIONS: Statins may have multifactorial effects on dementia but not MCI risk. Future interventions may be warranted, and research should focus on optimal serum TC, HDL-C:TC ratio and TC change trajectories.
Authors: B A in t' Veld; A Ruitenberg; A Hofman; L J Launer; C M van Duijn; T Stijnen; M M Breteler; B H Stricker Journal: N Engl J Med Date: 2001-11-22 Impact factor: 91.245
Authors: Miia Kivipelto; Eeva-Liisa Helkala; Mikko P Laakso; Tuomo Hänninen; Merja Hallikainen; Kari Alhainen; Susan Iivonen; Arto Mannermaa; Jaakko Tuomilehto; Aulikki Nissinen; Hilkka Soininen Journal: Ann Intern Med Date: 2002-08-06 Impact factor: 25.391
Authors: Ihab Hajjar; Jeannie Schumpert; Victor Hirth; Darryl Wieland; G Paul Eleazer Journal: J Gerontol A Biol Sci Med Sci Date: 2002-07 Impact factor: 6.053
Authors: Melinda C Power; Andreea Rawlings; A Richey Sharrett; Karen Bandeen-Roche; Josef Coresh; Christie M Ballantyne; Yashashwi Pokharel; Erin D Michos; Alan Penman; Alvaro Alonso; David Knopman; Thomas H Mosley; Rebecca F Gottesman Journal: Alzheimers Dement Date: 2017-09-12 Impact factor: 21.566
Authors: Zachary A Marcum; Rod Walker; Jennifer F Bobb; Mo-Kyung Sin; Shelly L Gray; James D Bowen; Wayne McCormick; Susan M McCurry; Paul K Crane; Eric B Larson Journal: J Am Geriatr Soc Date: 2018-10-05 Impact factor: 5.562